ZAQS.ORG

BioCryst is profitable. Now it wants to buy more rare disease drugs

1 day ago

How Taylor Farms became integral to America's food supply system

1 day ago

FDA approves daily HIV pill from Gilead designed to simplify treatment

1 day ago

HHS plans new FDA leadership roles for technology and drugs, sources say

1 day ago

Why vaccination rates are falling in the U.S.

3 days ago

BioMarin to acquire Alesta Therapeutics for $275 million

8 days ago

Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar

9 days ago

Hims & Hers CEO says FTC lawsuit misunderstands how the company works

10 days ago

The startup using AI to help rare disease families develop custom treatments

11 days ago

Court rules companies can't import Gilead medications from overseas

11 days ago

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

16 days ago

Trump administration ends Medicaid, CHIP funding for gender-affirming care for children

17 days ago

We're lifting our price target on Cardinal Health after issuing rosy profit guidance

17 days ago

Trump wants to split the MMR vaccine. Experts say that's unlikely

17 days ago

Jazz Pharmaceuticals to buy Actio Biosciences for $820 million

17 days ago

Eli Lilly takes weight-loss pill battle global

17 days ago

Trump signs order calling for fewer childhood vaccines, falsely linking shots to autism

18 days ago

New genetic tests are catching rare diseases before symptoms start

18 days ago

Why we like Boeing's latest deal — plus, what to expect from this health stock

18 days ago

Hunter Biden says Joe Biden's cancer has spread further, 'very painful'

18 days ago

Cyclospora fears lead consumers to lose their appetite for salads

21 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

22 days ago

Sen. Mitch McConnell says he's left rehab, will work from home

22 days ago

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

22 days ago

Divide between Eli Lilly and Novo Nordisk is widening after latest earnings

22 days ago

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

22 days ago

This stock is more than a way to play GLP-1 boom

23 days ago

Bank of America spends $250M a year on GLP-1 drugs for its employees, CEO says

23 days ago

Eli Lilly blows past estimates, raises outlook on Zepbound and Mounjaro sales

23 days ago

CVS blows past estimates, hikes guidance as insurance unit continues to improve

24 days ago

Novo CEO defends economics of Wegovy pill as lower prices weigh on sales

24 days ago

Chipotle stock falls on potential link to salmonella outbreak in Minnesota

24 days ago